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Abstract: Recent years have brought great focus on the development of drug delivery systems 
based on extracellular vesicles (EVs). Considering the possible applications of EVs as drug carriers, 
the isolation process is a crucial step. To solve the problems involved in EV isolation, we developed 
and validated a new EV isolation method— low-vacuum filtration (LVF)— and compared it with 
two commonly applied procedures— differential centrifugation (DC) and ultracentrifugation (UC). 
EVs isolated from endothelial cell culture media were characterized by (a) Transmission Electron 
Microscopy (TEM), (b) Nanoparticle Tracking Analysis (NTA), (c) Western blot and (d) Attenuated 
Total Reflection Fourier-Transform Infrared Spectroscopy (ATR-FTIR). Additionally, the membrane 
surface was imaged with Environmental Scanning Electron Microscopy (ESEM). We found that LVF 
was a reproducible and efficient method for EV isolation from conditioned media. Additionally, 
we observed a correlation between ATR-FTIR spectra quality and EV and protein concentration. 
ESEM imaging confirmed that the actual pore diameter was close to the values calculated theoretically. 
LVF is an easy, fast and inexpensive EV isolation method that allows for the isolation of both ectosomes 
and exosomes from high-volume sources with good repeatability. We believe that it could be an 
efficient alternative to commonly applied methods.
Keywords: dialysis membrane; ectosomes; exosomes; FTIR; infrared spectroscopy; purification
1. Introduction
Extracellular vesicles (EVs) are defined as bilayer cell membrane fragments released into the
extracellular space [1] . The number and composition of EVs can vary, depending on the cells they
originate from and the physiological or pathological conditions [2,3] . In experimental conditions,
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EVs are released into cell culture media, producing a conditioned medium [4- 7]. The classification of 
EVs is still under debate and reaching a common classification is complicated. To solve this awkward 
situation, MISEV 2018 guidelines were published, providing an extensive and complete characterization 
of EVs and their classification according to different parameters [8]. Large variation in size, composition 
and function has been found among the three types of EVs (Table 1).
Table 1. Characterization of EV populations according to diameter, biogenesis, physiological role, cargo 
and typical markers.
Exosomes Ectosomes Apoptotic Bodies
Diameter 30-100 (nm) 100-1000 (nm) 1000-5000 (nm)
Release mechanism Inside the cell in multivesicular bodies blebbing of the cell membrane
Cell fragments generated 
during cell apoptosis
Role Cell-to-cell communication Cell-to-cell communication Phagocytosis facilitation
Cargo DNA, RNA, proteins [9,10] 
Tetraspanins: CD9, CD63,
DNA, RNA, proteins [9,10] Cell organelles, nuclear fraction [9]
Markers CD81, Hsp70, Hsp90, Alix, 
Tsg 101, flotilin [11]
Integrins, selectins, Arf-6 Thrombospondin and C3b
EVs are widely studied because of their involvement in cell-to-cell communication [12]; tumor 
progression [13], and their possible application as biomarkers [14] or drug delivery systems (DDS) [15]. 
While studying the functional differences between the different types of EVs, it is crucial to use an 
appropriate isolation method that allows for obtaining a homogenous EV population. Unfortunately, 
this is a challenging task and the contamination of different EV types is very often observed [16].
An additional difficulty is the isolation of EVs from large-volume sources, or a situation when a 
large number of EVs is required for downstream analysis. In 2016, a worldwide study on applied EV 
isolation methods was performed among the members of the International Society of Extracellular 
Vesicles (ISEV) [17]. The study showed that 81% of respondents isolate EVs from conditioned media. 
Additionally, 71% of respondents isolate EVs from sources with starting volumes exceeding 5 mL 
(sometimes even up to 100 mL). According to this worldwide study, the most popular method is 
ultracentrifugation (81%  of respondents), in which the processing of high-volume samples can be 
difficult because of the relatively small size of the ultracentrifuge tubes usually used. Moreover, 
ultracentrifugation is a low-yield method and is characterized by high levels of contamination due to 
the coprecipitation of proteins [8,9,18,19].
Working with high-volume sources such as conditioned cell culture media, we propose a new 
method of EV isolation that allows for EV concentration in a relatively short time. Low-vacuum 
filtration (LVF) is a modification of the hydrostatic filtration dialysis (HFD) method described by 
Musante et al. [20], extended by the application of low vacuum (-0 .3  (bar)) in order to obtain faster 
filtration, which can limit the influence of isolation time on the changes in the sample [21]. The filtration 
system (Figure 1) consists of a closed cell culture media container from which, through a coupler, 
cell culture media flows into a dialysis membrane, where filtration is facilitated by the negative 
pressure in the vacuum chamber generated by the pump. The dialysis membrane is closed with a 
clamp. During the filtration process, the cell culture media soaks through micropores and EVs are 
collected within the membrane, which leads to sample concentration. The final volume of a sample 
may be reduced to 1 (mL)). Thanks to an additional step, membrane washing, the reduction of protein 
contamination (category 3 proteins [9]) in the sample can be achieved.
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Figure 1. Low-vacuum filtration (LVF) system: (a) closed liquid container; (b) a coupler connecting the 
dialysis membrane with the liquid container; (c) dialysis membrane; (d) a vacuum chamber; (e) a clamp 
closing the membrane; (f) a pump.
"The aim of this study was to compare; the efficiency; of three; methods of EV isolation: LVF, 
differential centrifugation and ultracentrifugation. EVs were isolated from human umbilical endothelial 
vein cells (HUVEC) conditioned media, and the obtained EV samples were compared in terms of 
the following parametets: size distribution, morphology, concentratisn and homogeneity of the EV 
populations. We also applied Attenuated Total Reflection Fourier-Transform Infrared Spectroscopy 
(ATR-FTIR) for EV characterization in order to assess biochemical composition to compare the 
three methods.
2. M aterials and Methods;
2.1. Cell Culture
Umbilical cords were collected during C-section performed between the 38th and the 42nd weeks 
of normal pregnancy and stored in Hank's balanced salt solution at 4 (°C) until HUVEC isolation. 
For cell digestion, an umbilical vein was injected with prewarmed (37 (°C)) 0.25% trypsin (cat. No. 
85450C, Sigma AldricZ, Sit. Louis, MU, USA) with EDTA (300 (mg/L)) (cat. No. E6758, Sigma Aldrich, 
St. Louis, MI, USA) mixed with cell culture medium 199 (cat. No. M7S53, Sigma Aldrich, St. Louis, MI, 
USA) 1.:1. Umbilical cords were incubated at 37 (°C) in PBS (phosphate buffered saline) for 30 (min); 
afterwards, the cells were washed out from the vein, collected in a 50 (mL) Falcon tube and centrifuged 
at 250 (g) for 15 (min). Tire cell pellet w at suspended in culture medium and cells were seeded into 
culture flasks.
HUVECs were cultured Sis a 75 (cm2) flask with the 1:1 mixtude yf 199 medium end human 
enyothelium Serum-Free Medium (SFM; cat. Nz. 11111044, GIBCO, Gaithersburg, MD, UZA), 
supplemented with 10% Fetal Bovine Serum (FBS; cat. No. S181B-500, Biowest, Nuaille, France), 
penirillin/streptzmycin (cat. No. P0781 BioReagent, Montigny le BretonneuXi France) at a concentration 
of 10,000 (units/L) (pen icillin) and 1 (mg/L) (streptomycin) and 2 (mM) of L-glutamine (cat. No. 17-605E, 
BioWhitaker, Lonza, Basei, Switzerland).
Before the sample collection, HUVECs were s i rum-starved for 124 h to obtain synchronization 
and avoid contamination by serum EVs [22,23]. Conditioners media were pulled trom twelve bottlts 
and divided into three equal poLtions, one for zach method of isolation, to obtain the same starting 
material composision in a volume of 40 (mL).
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2.2. Extracellular Vesicle Isolation
Every sample, before the procedure, underwent three preparatory centrifugations (Figure 2) . 
In order to remove intact cells, cell debris and apoptotic bodies, samples were centrifuged successively 
at 400 (g) (10 (min)), 3100 (g) (215 (min)) and 7000 (g) (20 (min)) at 4 (°C).
Figure 2. Scheme of the experimental design. After conditioned media collection, the samples 
underwent preparatory centrifugations to remove cells, ceil 1 eragmente and apoptotic bodies. After tire 
preliminary steps, EVs were isolated accoeding to the proc edure for each method. PBS (phosphate 
beffered salinn).
2.2.1. Ultracentrifugation (UC)
After the initial centrifugation steps, samples were transferred to 1.5 (mL) top -opened centrifuge 
tuber and spun for 1.5 (h) ar 150,000 (g) at 4 (°C) (Sorvall MX 1550-+- Micro-Ultracentrifugef Thermo 
Fisher Scientific, Waltham, MA, USA). EV pellets were suspended in 50 (fL ) of PBS, collected into one 
tube and spun once anain under the same conditions. Samples were prepared in triplicaie and pellets 
were stoeed at -8 0  (°C) for downstream analyris.
2.2.2. Differential Centrifugation (DC)
Differential centrifugation was performed according to the previously described protocol [24]. 
After the three preparatory centrifugations, samples were transferred to 50 (mL) polycarbonate 
centrifuge lubes and centrifuged for 20 (min) at 18,000 (g) ae 4 (°C) (Sorvall LYNX 6000 Superspecd 
Centrifuge, Thermo Fisher Scientific, Waltham, MA, USA). Part of the supernatant was discarded 
and tire lower part of tire medium (1.5 (mL)) was centrifuged in Eppendorf "Tubes under tire same 
conditions (5804 R Centrifuge, Eppendorf, Hrmburg, Germany). The pellets were resuspend ed in
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1.5 (mL) of PBS and centrifuged again two times under the same conditions (Figure 2). Samples were 
prepared in triplicate and pellets were stored at -8 0  (°C) for downstream analysis.
2.2.3. Low-Vacuum Filtration (LVF)
LVF was performed on the dialysis membrane (cat. No. 131486, Spectra/Por Biotech) with MWCO 
(molecular weight cut-off) 1000 (kDa). The whole system was assembled as presented in Figure 1. 
After the preliminary centrifugations, 40 (mL) of sample was placed in the liquid container (in Figure 1a), 
filtered under low vacuum (-0 .3  (bar)) and subsequently washed with 15 (mL) of water. After the 
filtration, the samples, which had been prepared in triplicate, were stored at -8 0  (°C) for the downstream 
analysis. For the purpose of TEM imaging, the samples after the filtration were ultracentrifuged under 
the conditions described in Section 2.2.1.
2.3. Environmental Scanning Electron Microscopy (ESEM)
To evaluate the diameter of pores in the dialysis membrane, we applied Environmental Scanning 
Electron Microscopy (ESEM). A fragment of the dialysis membrane (1 X 1 (cm)) was placed on the SEM 
sample holder and the subsequent ESEM measurements were performed using the SEM Quanta 3D 
FEG microscope (FEI Company, Hillsboro, OR, USA) in use by the Department of Solid State Physics 
(Institute of Physics Jagiellonian University, Kraków, Poland). The ESEM images were collected by a 
Low-Vacuum Secondary Electron Detector (LVED) using an electron beam of 20 keV energy. During the 
measurement, the specimen was kept at 130 (Pa) of water vapor at room temperature.
2.4. Transmission Electron Microscopy (TEM)
Samples for TEM imaging were prepared as previously described [14] . Pellets of isolated EVs 
were fixed with 2.5% glutaraldehyde (cat. No. G5882, Sigma-Aldrich, St. Louis, MI, USA) in 0.1 (M) 
cacodylic buffer (cat. No. C4945, Sigma Aldrich, St. Louis, MI, USA) and then postfixed in 1% osmium 
tetroxide solution for 1 (h). In the next step, samples were dehydrated in ethanol and embedded in 
PolyBed 812 (cat. No. 08792-1, Polysciences, Warrington, PA, USA) at 68 °C. Ultrathin sections were 
placed on the 300 mesh grids, covered with formvar film and contrasted using uranyl acetate and lead 
citrate. Observations were performed using a JEOL JEM2100HT electron microscope (Jeol Ltd., Tokyo, 
Japan) with the accelerating voltage of 80 (kV).
Images were analyzed using Photoshop and CTAnalyzer software. Background was removed from 
the binarized images and EVs as single objects were counted automatically. Four different parameters 
were considered: diameter, area, solidity and eccentricity. Solidity was calculated according to the 
following equation:
area
solidity =  ---------------—-------------   (1)
area created by convex hull
This is a parameter describing the extent to which a shape is convex or concave. This parameter is 
equal to 1 for a convex shape with no irregularities, and equal to 0 for a concave shape with many thin 
insets [25] . Eccentricity was calculated according to the following equation:
minor axis length
eccentricity =  — ;-------—------------------------------------------------------------ - (2)
major axis length
which compares the length of the minor axis and major axis, providing information about the changes 
in the elongation of an object.
2.5. Nanoparticle Tracking Analysis (NTA)
NTA measurements were performed by means of the NanoSight LM 10 (Malvern Panalytical, 
Malvern, UK), coupled with a 405 (nm) laser. For the NTA analysis, 100 (gL) of each sample was 
diluted to the volume of 500 (gL) with filtered PBS. For each method, three samples were prepared and
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measured in five independent records for 30 (s). The measurements were analyzed using NTA 3.1. 
software, and calculated and normalized to the starting sample volumes. The final results were 
analyzed by means of OriginPro 2018 software.
2.6. Attenuated Total Reflection Fourier-Transform Infrared Spectroscopy (ATR-FTIR)
For the ATR-FTIR spectroscopy measurements, 5 (gL) of each sample in PBS was mounted and 
dried on the diamond crystal of the Nicolet 6700 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, 
MA, USA) to obtain a thin dry film. Measurements were performed immediately at room temperature 
and 256 scans were collected at a nominal resolution of 4 (cm-1). The analysis of the obtained spectra 
was performed using the OriginPro 2018 Software.
2.7. Electrophoresis and Western Blot
EV protein extracts (15 (gg) per sample) were diluted 1:1 in the Laemmli Sample Buffer 
(62.5 (mM) Tris-HCl, pH 6 .8, 1 (mM) EDTA, 10% glycerol, 2% SDS, 0.025% bromophenol blue 
with 5% p-mercaptoethanol), separated by electrophoresis using the 4-15% gradient Mini-PROTEAN 
TGX Stain-Free Protein Gels (cat. No. 4568085, BioRad Laboratories Inc., Hercules, CA, USA) and 
transferred to PVDF (polyvinylidene fluoride) membranes using the Mini-Protean 3 system (Bio-Rad 
Laboratories Inc., Hercules, CA, USA).
Western blot analysis was performed using the Lumi-LightPLUS Western Blotting Kit 
(Mouse/Rabbit) (cat. No. 12015218001, Roche, Basel, Switzerland). The blots were blocked overnight in 
1% BSA (bovine serum albumin) in Tris-buffered saline with Tween (0.05 (M) Tris-HCl, 0.15 (M) NaCl, 
0.1% Tween 20, pH 7.5), and using the Lumi-LightPLUS Western Blotting Kit (Mouse/Rabbit) were 
incubated for 1 h with primary antibodies against VCAM (vascular cell adhesion molecule) (dilution 
1:500, cat. No. sc-13160, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), Hsp70 (dilution 1:500, cat. 
No. sc-24, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), Arf- 6 (dilution 1:200, cat. No. sc-7971, 
Santa Cruz Biotechnology, Inc., Dallas, TX, USA), actin (dilution 1:200, cat. No. sc-47778, Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), CD81 (dilution 1:200, cat. No. MABF2061, Sigma Aldrich, St. 
Louis, MI, USA) and CD63 (dilution 1:500, cat. No. CBL553, Sigma Aldrich, St. Louis, MI, USA). 
After incubation with the primary antibodies, membranes were washed three times with Tween/TBS 
buffer and incubated for 1 (h) with an appropriate horseradish peroxidase (HRP)conjugated secondary 
antibody (Lumi-LightPLUS Western Mouse/Rabbit Blotting Kit) diluted 1:250 in 1% BSA in TBS/Tween 
buffer. Afterwards, incubation membranes were washed three times in the TBS/Tween buffer and three 
times in TBS buffer (0.05 M Tris-HCl, 0.15 M NaCl, pH 7.5. Immunopositive bands were visualized 
using Lumi-Light Reagent (Roche, Basel, Switzerland) and the ChemiDoc™ XRS+ System (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). The relative levels of protein content were determined using 
Image Lab software. Individual protein levels were normalized to the total intensity of the bands on a 
given line, detected in the gel after electrophoresis.
2.8. Ethical Statement
The collection of umbilical cords for this study was approved by the Bioethical Committee of 
Jagiellonian University in Kraków on 26 April 2016 and written informed consent for publication 
must be obtained from participating patients. A  written informed consent for publication had been 
obtained from participating patients and patient details had been anonymized. Permission number 
122.6120.78.2016 was valid until 30 April 2018 and the collection of umbilical cords has been performed 
within the validity period.
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3. Results
3.1. Evaluation o f Dialysis Membrane Pore Diameter with ESEM
ESEM was used to visualize pores in the dialysis membrane. Figure 3 shows an exemplary 
image obtained in ESEM. ESEM measurements reveal the irregular structure of the membrane with 
pores varying in diameter (from 20.59 (nm) to 51.05 (nm)). The; average pores size; calculated from the 
50 randomly selected pores was 28.39 ±  9.63 (nm).
Figure 3. An exemplary Environmental Scanning Electron M icroscopy (ESEM) micrograph of the 
dialysis membranes surface, with thes sizes of several pores indicated.
3.2. EV Visualization with TEM
TEM was used to confirm the presence of EVs in the analyzed samples. Figure 4 shows 
representative images of EVs isolated by differential centrifugation, LVF and ultracentrifugation. 
Additionally, in order to investigate the influence of the applied methods on morphology of EVs, 
we compared their area, eccentricity and solidity.
The highest numbers of particles detected in the TEM samples were observed for EVs isolated by 
differential centrifugation (52 particles/image) and LVF (18 particles/image); the number of particles 
was the lowest for samples isolated by ultracentrifugation (5 particles/image). Additionally, the electron 
density of EVs was the highest for the LVF method and the lowest for ultracentrifugation. The average 
diameter of EVs and size distribution varied between samples (Figure 4) . The largest EVs, with an 
average diameter of 227 ±  175 (nm) and a median diameter of 175 (nm), were observed in the samples 
isolated by differential centrifugation. In samples obtained by LVF, EVs had an average diameter of 
114 ±  69 (nm) and a median diameter of 100 (nm). In ultracentrifugation samples, the smallest EVs 
observed had an average diameter of 78 ±  44 (nm) and a median diameter of 72 (nm). The area of 
EVs corresponded to the mean diameter and to shape parameters, which were very similar across the 
analyzed groups (see the table in Figure 4). For each isolation method, we observed the elongation of the 
EVs: the eccentricity parameter varied between 0.57 ±  0.15 for differential centrifugation and 0.60 ±  0.15 
for LVF. We did not observe differences in the solidity of particles. In differential centrifugation and 
LVF, EVs had the same solidity of (0 . 92 ±  0.07 and 0.92 ±  0.03, re spectively EVs isolated by tire 
ultracentrifugation method had a solidity of 0.91 ±  0.02.
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Area (nm2) Eccentricity (-) Solidity (-)
Differential
44193 + 72727 0.58 + 0.16 0.92 + 0.07
centrifugation
LVF 12231 ± 1 2 0 1 8 0.60 ± 0.15 0.92 ± 0.03
Ultracentrifugation 4647 ± 3918 0.57 ± 0.15 0.91 ± 0.02
Figure 4. Representative TEM images and sizes distributions, with the log-normal fit parameters, for tire 
EVs isolated using ta) differentiai centrifugation; (lb) LVF; (c) Ultracentrifugation. The: table below 
the images presents the mean area, eccentricity and solidity of the EVs obtained using these three 
isolation methods.
3.3. NTA Measurements o fE V  Concentration and Size
EV concentrations were measured for the starting samples and for the samples after isolation 
using NTA. The average concentrations of EVs in the samples after ultracentrifugation was 1.71 X 1010
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± 1.23 X 108 (particles/mL). The average size of the EVs detected was 224 ±  112 (nm), and EVs with 
diameter lower than 100 (nm) were not detected. "We observed a 35-fold increase in EV concentration 
in cem parisonto the starring sample.
For samples isolated by the LVF method, the average concentration of EVs was 7.96 X 109 ± 
5.812 X 107 (particles/mL). The average size was 260 ±  1°2 (nm), and particles with a diameter lower 
than 100 (nm) w err nee deteeted either. We observed a 22'-fold increas e in particle concentration in 
comparison to the starting sample.
Thh lowest conrentratians (4. 74 X 109 ±  3. 91 X 107” (particles/mL)) were found for samples obtained 
by differential centririigation. Average EV hize was equal to 255 ±  142 (nm), and unlike the case of the 
other metheds, EVs with e diameter lower 7han s00 (nm) were detected. We observed a 13-fold increase 
in EV concentration in comparison to the starting sample. High variations in size and concentration 
were observed (Figure 5).
Figure 5. Results of the Nanopartide Tracking ./Analysis (NTA). (a) Differential centcifugation; (b) LVF; 
(c) Ultracentri7ugation; (d) Comparison of1 the -solation methods tented. The ltnes indicate tha mean 
concentrations (linn) of the three samples. Each sample was recorded for 30 s and the measurement 
was repeated 15 times. The SDs of the three independene measurements are presentee- as the colored 
areas around the mean concentration line. The -able presents the averege concentrations of EVs in the 
samples after isolation; sample condensation, defined as the relative increase ini the number o7 EVs 
in the sample after isolation compared to their concentration in the starting samples; the average EV 
diameter; and the size mode.
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3.4. Infrared Spectra o f EVs
Infrared (IR) spectroscopy provides general information about chemical composition with 
additional details regarding the quality of the isolated EVs, especially in the context of the protein 
and lipid content (Table 2). Two amide peaks originating from peptides—the amide I band, at around 
1652 (cm-1) [26], and the amide II band, at around 1542 (cm-1) [26]—were the main component of the 
EV infrared spectra (Figure 6a,b). Additionally, the band at around the 3286 (cm-1 ) peak belonging to 
amide A [26] was observed. The highest intensities for the aforementioned peaks, associated with 
proteins and peptides, were detected for the EVs isolated by LVF and ultracentrifugation. In differential 
centrifugation samples, those peaks were barely distinguishable, showing low intensity. In the LVF 
samples, additional peaks were observed at 1309 (cm-1) and 1240 (cm-1), which were attributed to 
amide III (C-N  stretching mode of proteins).
We observed lipid bands represented as four peaks originating from the stretching vibrations of 
lipid acyl chain groups (Figure 6a,b). The peaks at 3076 (cm-1) and 2959 (cm-1) are generated by CH3 
asymmetric stretching, while the peaks around 2930 (cm-1 ) and 2869 (cm-1) are generated by CH2 
asymmetric and symmetric stretching vibrations. Additional lipid bands originating from CH2 [27] 
and CH3 [27] bending vibrations in the lipid acyl chains were distinguished around the 1450 (cm-1) 
and 1397 (cm-1) peaks, respectively. As in the case of the protein bands, lipid bands were detected 
in the LVF and ultracentrifugation samples and were barely distinguishable in the samples of EVs 
isolated by the differential centrifugation method.
Table 2. FTIR peak assignment.
Wavenumber
(cm-1) Definition of the Spectra Assignment
3286
3076
Overlapping -OH stretching vibrations and N-H stretching vibrations from peptide groups 
of proteins (amide A) [26]
CH3 asymmetric stretching vibrations from lipids with low contribution from proteins,
2959 carbohydrates and nucleic acids [28]
2930 CH2 asymmetric and symmetric stretching vibrations from lipids with low contribution from
2869 proteins, carbohydrates and nucleic acids [29]
1652 C=O stretching vibrations from peptide backbone (amide I) [26]
1542 N-H bending vibrations from peptide groups (amide II) [26]
1450 CH2 bending (scissoring) vibrations from lipid acyl [27]
1397 CH3 bending vibrations from lipids and proteins [27]
1309
1240 C-N stretching mode of proteins, indicating mainly a-helical conformation (amide III) [30]
In order to perform further ATR-FTIR analysis for amide (1450-1750 (cm-1)) and lipid (2800-3000 
(cm-1)) bands, we performed automatic baseline subtraction and Gaussian function fittings to all peaks 
in the analyzed ranges (Figure 6c). Based on the areas under the curves, we calculated the amide 
I/lipids ratio and obtained the highest ratio for the LVF and ultracentrifugation samples: 10.22 and 
6.31, respectively. IR spectra for EVs isolated by differential centrifugation were characterized with the 
lowest ratio (4.15) and the total area under the analyzed peaks was much lower than for other samples.
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Figure 6. Results of the FTIR analysis. (a) Average infrared spectra for EVs isolated with the tested 
methods (line) with the SD of three independent measurements (upper and lower edges of the colored 
areas); (b ) Comparison of the EVs spectra with the spectea of HUVE C cells with the assignment of the 
main peaks; (c) Example of the Gaussian function fitting for amide I/lipids ratio calculation w ith results 
(see the table). HUVEC: human umbilica/ endothelial vein cells.
3.5. EV Protein Markers
In order to investigate the type of EVs present in the isolated samples, we performed a Western 
blot analysis. The total protein amount in the EV samples was measured by the BCA method and 
the highest protein toneentration was observed in the LVF samples (3.73 ±  0.63 (mg/mL)). In the 
ultracentrifugation and deferential centrifugation samples, protein amounts were sim il/r: 2.4( ±  1.70 
(mg/mL) and 2.40 ±  0.23 (mg/mL), respectively (Figure 7a). To /onfirm  the endothelial origin of 
the isolated EVs, vascular cell adhesion molecule 1 (VCAM-1) was used as an endothelial marker. 
High-intensity bands for VCAM-1 were observed in the differential centrifugation and LVF samples: 
1.50 ±  0.16 (AU) and 1.38 =/ 0.24 (AU), respectively. The intensity of tg/ee bands was significanily 
higher than in the ultracentrifugation sample/ (0.819 ±  0.11 (AU() (Figure 7b ). Addffionally, in the: 
tested samples, actin bands with sim ila/ intensity were detected: 1. 33 ±  0 .33 (AU) for differential 
centrifugation, 0.88 ±  0.07 (AU) for LVF and 1.19 ±  0.17 (AU) for ultracentrifugation.
We used Arf-6 as an ectosomal marker and detected Arf-6-positive bands with low .ntensity for 
all tested samples (0.7 ±  0.02 (AU) for differential centrifugation, 0.5 ±  0.02! (AU) for LVF, 0.7 ±  0.04 
(AU) for ultracentrifugation) (Figure 7b). As exosome markers, we used Hsp70, CD63 and CD81. 
Hsp70 bands with high intensity were detected in the LVF samples (0.418 ±  0.14 (AU)), compared lo 
the ultracentrifugation and differential centrifugation samples: 0.23 ±  0.12 (AU) vs 0.04 ±  0.01 (AU), 
p <  0.05. Bands for the CD81 marker 1/ad significantly highee intens ity in the LVF (0.23 ±  0.°1 (AU)) 
and ultracentrifugation samples (0.19 ±  0.01 (AU)) compared to the differential centrifugation samples 
(0.13 ±  0.02, p <  0.05). There were no statistically significant differences in the intensity of CD63 band 
intensity between the methods: differential centrifugation (1.56 ±  0.36 (AU)), LVF (0.96 d 0.29 (AU)) 
and ultracentrifugation (0.85 ±  0.22) (Figure 7b).
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Figure 7. Results of the Western blot analysis. (a) Images of the membrane after blotting and the gel 
after electrophoresis with clearly visible differences in bands' intensities between the EV samples 
isolated by d ifferent methods; (b) Band intensity analysis. Data are presented as mean values (c olumn) 
and SDs (whiskers). The analysis was performed using the Kruskal-Wallis test. Differences berween 
subgroups were tested with Dunn's posthoc test, dnd statistically? significant differences are marked 
with an asterisk (p < 0.05).
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4. Discussion
The interest in extracellular vesicles has grown over the last years [31], mostly because of their 
involvement in cell-to-cell communication [32], cancer progression [33] and immunosuppression [34], 
and due to their great potential as DDS [15,35] . Besides the recent intense development in EV isolation 
micromethods, there is an unmet need to develop more ef cient and repeatable EV isolation and 
concentration methods for application with high-volume sources, suitable not only for proteomic 
analysis but also for drug delivery purposes [35,36]. In this study, we have developed and validated 
a system that is dedicated to EV concentration from high-volume sources of conditioned media: 
low-vacuum filtration (LVF).
As we have shown in this study, EVs can be concentrated from high-volume culture supernatants 
on dialysis membranes (MWCO =  1000 (kDa)) by means of the LVF method. We also compared 
EVs isolated using LVF with those isolated using the most commonly used alternative methods, 
ultracentrifugation and differential centrifugation [18], and found that both protein and lipid contents 
were higher in the LVF samples in comparison to the other isolation methods. FTIR spectroscopy was 
used to assess the quality and repeatability of EV isolation and molecular content analysis.
It has been reported that ultrafiltration is a good alternative to the ultracentrifugation 
method [18,20,37]. However, the isolation of EVs through filtration could be challenging, mainly due 
to the need to rinse EVs from the membrane with additional chemical compounds [38], membrane pore 
plugging resulting in low isolation yields [39], the possible changes in EV morphology caused by the 
application of high pressure [40] and time-consuming procedures [20] . LVF can solve these problems 
because of its important advantages. There is no need to wash EVs from the membrane using chemical 
compounds, as only water is used to rinse additional proteins from the sample. Membrane plugging, 
prevalent in other methods, was not observed in our method either. In terms of the yield of isolation, 
LVF is comparable to ultracentrifugation and significantly better than the differential centrifugation 
method (shown in Figure 5). As compared to the initial sample, EV concentration was 35 times higher 
in the case of the ultracentrifugation procedure, 22 times higher in the case of LVF and 12 times higher 
in the case of differential centrifugation.
The diameter of membrane pores, measured by means of ESEM, varied between 20 and 50 (nm). 
TEM images of LVF samples confirmed the presence of EVs with a minimal diameter of 20 (nm) 
(TEM, Figure 4), while NTA analysis showed the presence of EVs with a minimal diameter of 66 (nm) 
(raw data). It can therefore be assumed that even the smallest EVs can be retained in the filtered media. 
Moreover, we assessed the impact of applied low pressure on EV shape by means of TEM imaging and 
did not observe any increase in EV shape diversity in the LVF samples (defined in terms of eccentricity 
and solidity as shape parameters; shown in Figure 4). However, it is important to consider that TEM is 
a 2D method and the shape of an object shape is analyzed in sectioned samples. This means that the 
obtained image is a contour and depends on the orientation of the object.
Another advantage of the LVF method is the isolation time. In our method, pressure is used to 
facilitate filtration and can speed up the filtration process by up to four-fold (for 100 (mL), reducing 
time from 8 (h), as for the standard methods, to 2 (h) with the addition of additional pressure) [20] . 
This facilitation, however, is possible only by means of dedicated centrifuges which are very expensive 
and not readily available.
In order to confirm that both ectosomes and exosomes were present in the isolated EV samples, 
and in order to confirm it not only by means of the size distribution methods described above, 
we applied a Western blot to detect specific exosome and ectosome markers: Hsp70, CD81, CD63 
and Arf-6 (Figure 7). We found that LVF samples had the highest intensity of Hsp70 and CD63 bands, 
while the Arf-6 and CD81 bands had similar low intensity in the samples isolated by all tested methods. 
Ectosome samples are usually enriched in Arf-6, the protein involved directly in the shedding of 
plasma membrane-derived EVs, but not in exosome biogenesis [24] . In our study, relatively low 
expression of Arf-6 in comparison to the exosome marker CD63 was observed, showing that exosome 
proteins dominated in all samples. In contrast, actin, known as an ectosome marker, was detected with
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high intensity. We can conclude that actin-based contraction is necessary for exosome secretion and 
contamination with beta-actin is possible in exosome fractions.
Heat shock proteins (Hsp70) are present in a variety of EVs; nonetheless, these proteins are 
representative for a canonical exosome [11], and so are tetraspanins (CD81, CD63), which are considered 
to be exosome biomarkers (Category 1 a: non-tissue-specific transmembrane proteins) [9]. Predictably, 
HUVEC-derived EVs had higher concentrations of CD63 than CD81 proteins. CD63 is primarily an 
intracellular tetraspanin, mainly found in late endosomal and lysosomal compartments. In endothelial 
cells, CD63 was identified as a component of Weibel-Palade bodies [41]. In contrast, CD81 is present in 
the endothelium of early human atherosclerotic lesions [42] .
Therefore, we conclude that the samples isolated by LVF contained the highest concentrations 
of exosomes, while ectosome concentration was similar in all samples regardless of the isolation 
method used. It has been postulated that additional centrifugation or filtration steps should be used 
in order to avoid ectosome contamination in the ultracentrifugation isolation method [43] . In this 
study, we observed that bands attributed to the exosome marker in the differential centrifugation 
samples were more than ten times less intensive than in the case of samples isolated by LVF. Based 
on our findings, we also recommend using additional centrifugation at 18,000 (g) in order to remove 
ectosomes an additional preliminary centrifugation if the goal is to obtain clear exosomal samples in 
further isolation steps in ultracentrifugation, as well as before concentration by LVF [8,22] .
In our study, we used FTIR as a new approach. Previously, it was shown that FTIR is useful as a 
screening method for resolving EV protein composition and structure (p-sheet) [28]. In the isolated EV 
samples, we analyzed three strongest peptide peaks: amide I (1652 (cm-1)), amide II (1542 (cm-1)) 
and amide A (approx. 3286 (cm-1)). The highest intensity of these peaks was measured for EVs 
isolated by LVF and ultracentrifugation. Protein bands were barely distinguishable in the spectra of 
samples obtained by differential centrifugation. Like protein bands, typical lipid bands (3076 (cm-1), 
2959 (cm-1), 2930 (cm-1), 2869 (cm-1), 1450 (cm-1)) were clearly visible for the samples isolated by LVF 
and ultracentrifugation. Additionally, in the LVF spectra, additional peaks appeared at 1309 (cm-1) 
and 1240 (cm-1), which can be attributed to amide III (C-N stretching mode of proteins). The presence 
of the amide III peak may indicate the presence of a-helix structures in the sample.
Moreover, we applied FTIR analysis not only to assess sample quality, but also to measure protein 
concentration (the amide-to-lipids ratio). Protein concentration correlated with the amide I-to-lipids 
ratio for LVF and ultracentrifugation samples (Figures 6 and 7). On the other hand, samples isolated 
by differential centrifugation and ultracentrifugation had similar protein concentrations. Nevertheless, 
the amide-to-lipids ratio was significantly different. This is probably a result of the low quality of 
the samples and the low resolution of the FTIR spectra, where the peaks were barely distinguishable, 
but calculations of the area under the curve and the ratio between these two values were still possible. 
The FTIR spectra confirm that the LVF method is reproducible, if other possible error-causing factors 
(temperature, time of processing, preanalytical errors and the human factor) are controlled.
Plasma membrane-derived vesicles are often used as a model system for the biochemical 
and biophysical investigation of membrane proteins and membrane organization. The most naive 
and unprocessed vesicles from eukaryotic cells are produced by mechanical extrusion of anuclear 
erythrocytes. Such an approach provides a simple and broadly applicable strategy to isolate and 
concentrate proteolipidic systems similar to plasma membranes [44] . The other strategy, utilizing 
a hypertonic calcium chloride buffer to obtain large vesicles (several pm in diameter), was used 
to quantitatively load protein cargo [45] . In clinics, a bioreactor-based, large-scale production of 
clinical-grade exosomes was established to generate engineered exosomes with the ability to target 
oncogenic KRAS (iExosomes) [46]. For such clinical applications, cytochalasin B-induced microvesicles 
(CIMVs) were found to be effective drug delivery mediators [47]. CIMVs differ from naturally released 
EVs as they are produced without active cargo sorting machinery from numerous cell types, including 
HUVECs [48] . The LVF method can be easily utilized to rescale EV purification for clinical DDS.
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5. Conclusions
The LVF method can be recommended as a workflow for EV isolation from conditioned media in 
high-volume samples. This method is easy, fast and low-cost, allowing for the isolation of both ectosomes 
and exosomes from high-volume sources, and could be an efficient alternative to commonly applied 
methods. These characteristics, especially high reproducibility, may lead to the future applications of 
this method as an isolation protocol in the development of drug delivery systems based on EVs.
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